The journal retracts the 04 March 2019 article cited above.
Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies.
This retraction was approved the Chief Executive Editor of Frontiers. The authors received a communication regarding the retraction and had a chance to respond. This communication has been recorded by the publisher.
Summary
Keywords
Santacruzamate A, Aβ25-35, APPswe/PS1dE9 mice, KDEL receptor, Mia40
Citation
Frontiers Editorial Office (2024) Retraction: Santacruzamate A Ameliorates AD-Like Pathology by Enhancing ER Stress Tolerance Through Regulating the Functions of KDELR and Mia40-ALR in vivo and in vitro. Front. Cell. Neurosci. 18:1505362. doi: 10.3389/fncel.2024.1505362
Received
02 October 2024
Accepted
02 October 2024
Published
08 October 2024
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
18 - 2024
Updates
Copyright
© 2024 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office research.integrity@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.